Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;44(2):279-297.
doi: 10.1016/j.ccm.2022.11.008. Epub 2022 Nov 28.

Antiviral Treatment of Coronavirus Disease-2019 Pneumonia

Christopher Radcliffe  1 , Maricar Malinis  1 , Marwan M Azar  2
Affiliations
Review

Antiviral Treatment of Coronavirus Disease-2019 Pneumonia

Christopher Radcliffe et al. Clin Chest Med. 2023 Jun.

Abstract

Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic.

Keywords: Bebtelovimab; COVID-19; Molnupiravir; Nirmatrelvir; Remdesivir; SARS-CoV-2; Tixagevimab/cilgavimab.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Timeline for SARS-CoV-2 antiviral therapies in the United States. FDA, US Food and Drug Administration; EUA, emergency use authorization; WHO, World Health Organization.
Fig. 2
Fig. 2
Mechanism of SARS-CoV-2 antiviral therapies.
Fig. 3
Fig. 3
Clinical pathway for management of outpatient persons with COVID-19. Clinical pathway as of May 16, 2022. Definitions for “severely immunosuppressed” and “very high risk” provided in Supplement Table 2. CrCl, creatinine clearance; ED, emergency department; EUA, emergency use authorization; HD, hemodialysis; PD, peritoneal dialysis.
Fig. 4
Fig. 4
Clinical pathway for preexposure prophylaxis with tixagevimab/cilgavimab. Clinical pathway as of May 16, 2022. HIV, human immunodeficiency virus; IVIG, intravenous immunoglobulin.
Fig. 5
Fig. 5
Clinical pathway for management of inpatient persons with COVID-19. Clinical pathway as of May 16, 2022. AKI, acute kidney injury; CrCl, creatinine clearance; ESRD, end stage renal disease; EUA, emergency use authorization; ICU, intensive care unit; IV, intravenous; NPO, nil per os; PO, per os.
See this image and copyright information in PMC

References

    1. WHO. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/ Available at: Accessed September 30, 2022.
    1. Nguyen K.H., Anneser E., Toppo A., et al. Disparities in national and state estimates of COVID-19 vaccination receipt and intent to vaccinate by race/ethnicity, income, and age group among adults ≥ 18 years, United States. Vaccine. 2022;40(1):107–113. (In eng) - PMC - PubMed
    1. Wagner C.E., Saad-Roy C.M., Morris S.E., et al. Vaccine nationalism and the dynamics and control of SARS-CoV-2. Science. 2021;373(6562):eabj7364. (In eng) - PMC - PubMed
    1. Gandhi R.T., Lynch J.B., Del Rio C. Mild or moderate covid-19. N Engl J Med. 2020;383(18):1757–1766. (In eng) - PubMed
    1. Berlin D.A., Gulick R.M., Martinez F.J. Severe covid-19. N Engl J Med. 2020;383(25):2451–2460. (In eng) - PubMed

Substances